<div><p><strong>Background</strong>: The American Association for the Study of Liver Diseases has stated that fostering a “supportive environment for transsexual individuals seeking hepatology care” is an important goal. However, the landscape of transgender patients with cirrhosis is largely unknown. We aimed to assess the clinical characteristics of transgender patients with cirrhosis and quantify their outcomes. </p>

<div><p><strong><b>Background:</strong> </b></p>
<p>Point-of-care echocardiography (POC-Echo) can be used to evaluate Cirrhotic Cardiomyopathy (CCM) and inferior vena cava (IVC) dynamics. The impact of cardiac function and IVC dynamics on cirrhosis progression towards refractory ascites and HRS-AKI is yet to be defined. This study aims to evaluate the utility of CCM markers and IVC changes, assessed by POC-Echo, in predicting adverse outcomes in patients with cirrhosis and ascites.</p>
<p></p>

<div><p><b>Background:</p> </b><p>A-LiNK (Autoimmune Liver disease Network for Kids) is a collaborative, multi-center learning health network uniting patients, parents, clinicians, researchers, and stakeholders to address gaps in care for children with Autoimmune Liver Disease. We seek to define predictors of optimal outcomes and determine current practices in Autoimmune Hepatitis (AIH).</p>

<div><p><strong><b>Background:</strong> </b>Metabolic dysfunction-associated steatohepatitis (MASH) diagnosis and scoring depend on invasive liver biopsies by measuring metabolic dysfunction-associated steatotic liver disease (MASLD) activity score (NAS) and fibrosis score. However, a quantitative estimation of the combined effect of clinically available laboratory measures and transient elastography parameters (controlled attenuation parameter [CAP] and liver stiffness score [LSM]) as a screening / diagnostic test for advanced MASH has been suggested.

<div><p><strong><b>Background:</strong> </b></p>

<div><p><b>Background:</p> </b><p>Living donor liver transplantation (LDLT) has been increasing in the United States (US). While data exists on longer-term patient and graft outcomes, a contemporary analysis of short-term outcomes is needed to better understand risk factors and opportunities for improvement.</p>

<div><p><b>Background: </b>Comorbidity plays an important role in the mortality of patients both on the waiting list and after liver transplantation (LT). To analyze the impact of comorbidities on LT, a prospective and multicentre study (HEPA_TIC) has been launched.</p>

<div><p><strong> </strong></p>
<p style="font-weight: 400;"><strong><b>Background:</strong> </b></p>

<div><p><b>Background: </b>New treatment concepts focus on enhancing rates of functional cure of chronic hepatitis B (HBV) with the aims of stopping nucleos(t)ide treatment (NA) with no risk of virological relapse or liver disease progression and further decreasing the risk of hepatocellular carcinoma (HCC). Induction of a CD8+ T cell response to HBV is likely a required mechanism to achieve a functional cure.

<div><p><b>Background: </b>While studies have associated social determinants of health (SDOH) with hepatocellular carcinoma (HCC) treatment delay of &gt;3 months, there is limited data on SDOH impacting expedited treatment and subsequent outcomes. This study investigates whether components of SDOH are associated with progression<span>-</span>free survival for HCC within Milan criteria and their effect on time to initiate HCC treatment.</p>